AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 14530608
Drug: Low-dose ACTH
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose ACTH test (LDAT)
Trial: 14530608
Drug: Standard-dose ACTH
RxNorm normalized name: ACTH
DrugBank: Corticotropin (DB01285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Standard-dose ACTH test (SDAT)
Trial: 6819275
Drug: Neutron therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neutron therapy (20 daily fractions over four weeks)
Trial: 6819275
Drug: Photon therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Photon therapy (20 daily fractions over four weeks)
Trial: 21525191
Drug: Calcium plus
RxNorm normalized name: O Calcium Plus D
DrugBank: Cupric oxide (DB11134)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcium plus vitamin D (CaD) supplements: 500 mg calcium carbonate plus 200 IU vitamin D(3) twice daily (1000 mg and 400 IU daily, respectively) for an average of 7.0 years.
Trial: 8814649
Drug: Ethanol (0.55
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ethanol (0.55 g/kg)
Trial: 8814649
Drug: Ethanol (0.55
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ethanol (0.55 g/kg) with deviant tones
Trial: 1325036
Drug: Azithromycin (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin (1 g once orally)
Trial: 1325036
Drug: Doxycycline (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxycycline (100 mg orally twice daily for seven days)
Trial: 30266729
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose RS2 (48 g daily for 2 weeks)
Trial: 30266729
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose RS2 (3 g/2,500 kcal daily for 2 weeks)
Trial: 25178924
Drug: O₃ (0.300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: O₃ (0.300 ppm) + DE (300 μg/m³)
Trial: 25178924
Drug: DE (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DE (300 μg/m³)
Trial: 21942262
Drug: bupropion (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bupropion (300 mg/day)
Trial: 19623601
Drug: Donepezil 5
RxNorm normalized name: donepezil 5 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Donepezil 5 mg/day for 6 weeks, then 10 mg/day thereafter
Trial: 17305413
Drug: Diclofenac potassium
RxNorm normalized name: Diclofenac Potassium
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Diclofenac potassium 12.5mg tablets
Trial: 17305413
Drug: Diclofenac potassium
RxNorm normalized name: Diclofenac Potassium
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Diclofenac potassium 25mg (2 tablets)
Trial: 17305413
Drug: Diclofenac potassium
RxNorm normalized name: Diclofenac Potassium
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Diclofenac potassium and ibuprofen
Trial: 12066736
Drug: Topical 4%
RxNorm normalized name: menthol topical 4% topical gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 4% amethocaine gel (Ametop)
Trial: 10223780
Drug: Ramipril (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ramipril (5 mg to 20 mg for 8 weeks)
Trial: 7910470
Drug: 0.1 mg
RxNorm normalized name: biotin 0.1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 mg suriclone
Trial: 7910470
Drug: 0.2 mg
RxNorm normalized name: niacin 0.2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 mg suriclone
Trial: 19178124
Drug: High-dose chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose chemotherapy (HDT) with peripheral blood stem cell transplant (PBSCT) support
Trial: 19178124
Drug: Standard chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard chemotherapy regimen (CHOP)
Trial: 9413023
Drug: GHB (gammahydroxy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GHB (gammahydroxy butyric acid) at a dose of 25 mg/kg body weight
Trial: 3464742
Drug: Stomatognathic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stomatognathic treatment
Trial: 24948347
Drug: Delayed-release cysteamine
RxNorm normalized name: cysteamine Delayed Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed-release cysteamine bitartrate (DR-CYS)
Trial: 20423222
Drug: AS03-adjuvanted vaccine
RxNorm normalized name: respiratory syncytial virus pre-fusion F protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AS03-adjuvanted vaccine (11.86 mg or 5.93 mg of tocopherol)
Trial: 20423222
Drug: Both AS03-adjuvanted
RxNorm normalized name: AS03 Adjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both AS03-adjuvanted and nonadjuvanted vaccines
Trial: 11784224
Drug: High daily
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High daily alcohol intake
Trial: 11784224
Drug: Uric acid
RxNorm normalized name: Uric acid
DrugBank: Uric acid (DB08844)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Uric acid (HR per 1 mmol/L increase)
Trial: 10362188
Drug: Low-dose argatroban
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose argatroban
Trial: 10362188
Drug: High-dose argatroban
RxNorm normalized name: Argatroban
DrugBank: Argatroban (DB00278)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: High-dose argatroban
Trial: 2187701
Drug: Dilevalol 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dilevalol 100 mg once daily
Trial: 2187701
Drug: Carteolol 10
RxNorm normalized name: carteolol 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carteolol 10 mg once daily
Trial: 6500777
Drug: Vincamine teprosilate
RxNorm normalized name: vincamine
DrugBank: Vincamine (DB13374)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vincamine teprosilate (Teproside) administered intravenously (i.v.)
Trial: 6500777
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered intravenously (i.v.)
Trial: 27310969
Drug: Infliximab (IFX)
RxNorm normalized name: Infliximab
DrugBank: Infliximab (DB00065)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Infliximab (IFX) at 5 mg/kg administered at weeks 0, 2, 6, and every 8 weeks thereafter until week 46; dose increased to 10 mg/kg for inadequate responders after week 30
Trial: 24047799
Drug: Rotarix vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rotarix vaccine
Trial: 22677811
Drug: Oral midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral midazolam (0.3 mg/kg, max. 15 mg)
Trial: 22677811
Drug: Very low
RxNorm normalized name: Very low fat spread
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Very low dose of N(2)O (10%)
Trial: 16103236
Drug: BQ‐123 (ET-1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BQ‐123 (ET-1 receptor blockade)
Trial: 8543520
Drug: Parent- and
RxNorm normalized name: C.I. direct red 28 parent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parent- and child-administered structured DSM-III-R DISC interviews
Trial: 30566363
Drug: Probiotics (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotics (2.5 × 10^9 CFU/g) containing 9 bacterial strains (Ecologic Barrier)
Trial: 29737292
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (not specified, likely placebo or standard treatment)
Trial: 26474430
Drug: Pregabalin (150-300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pregabalin (150-300 mg twice a day)
Trial: 23388562
Drug: Paclitaxel poliglumex
RxNorm normalized name: PACLITAXEL POLIGLUMEX
DrugBank: Paclitaxel poliglumex (DB13809)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paclitaxel poliglumex (PPX) 50 mg/m/wk with temozolomide 75 mg/m and radiation 2.0 Gy, 5 d/wk for a total dose of 60 Gy
Trial: 19496531
Drug: Xenogeneic (mouse)
RxNorm normalized name: house mouse skin extract
DrugBank: Mus musculus skin (DB10412)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xenogeneic (mouse) gp100 plasmid DNA injected intramuscularly at dosages of 100, 500, or 1,500 microg every three weeks for three doses.
Trial: 19496531
Drug: Human gp100
RxNorm normalized name: Insulin Human
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Human gp100 plasmid DNA injected intramuscularly at dosages of 100, 500, or 1,500 microg every three weeks for three doses.
Trial: 8121125
Drug: Aspirin (165
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (165 mg/day)
Trial: 8121125
Drug: Heparin (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin (1000 U/h)
Trial: 3478465
Drug: 2% citrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% citrate buffered dentifrice in a pluronic gel
Trial: 3478465
Drug: Dentifrice containing
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dentifrice containing 0.1% fluoride and 2% citrate buffer in a pluronic gel
Trial: 25856785
Drug: ARB +
RxNorm normalized name: revakinagene taroretcel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ARB + Hydrochlorothiazide (losartan 50 mg/hydrochlorothiazide 12.5 mg)
Trial: 23350826
Drug: Internet-based treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-based treatment programme (124 women)
Trial: 23350826
Drug: Postal treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postal treatment programme (126 women)
Trial: 21295409
Drug: Ivermectin/pyrantel pamoate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ivermectin/pyrantel pamoate chewable tablets
Trial: 21295409
Drug: Milbemycin oxime
RxNorm normalized name: Milbemycin Oxime
DrugBank: Milbemycin oxime (DB11531)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Milbemycin oxime flavored tablets
Trial: 21295409
Drug: Selamectin topical
RxNorm normalized name: selamectin Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selamectin topical solution
Trial: 21295409
Drug: Imidacloprid/moxidectin topical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imidacloprid/moxidectin topical solution
Trial: 19826203
Drug: Shape of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shape of the dose distribution (measured by lateral extent)
Trial: 19826203
Drug: Shape of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shape of the dose distribution (measured by longitudinal extent)
Trial: 19826203
Drug: Dose-surface histogram
RxNorm normalized name: sulfacetamide sodium Ophthalmic Solution [Sulfac]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose-surface histogram (DSH)
Trial: 19826203
Drug: Shape of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shape of the dose distribution
Trial: 16399182
Drug: Stiffer implants
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stiffer implants (rigidity 1.8)
Trial: 16399182
Drug: Regular implants
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular implants (rigidity 1.0)
Trial: 15565453
Drug: Administered dose
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered dose of 0.001 Sv
Trial: 11380543
Drug: Oil-in-water (o/w)
RxNorm normalized name: water, O-15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oil-in-water (o/w) cream applied 2x/day for 14 days in ICD study
Trial: 11380543
Drug: Oil-in-water (o/w)
RxNorm normalized name: water, O-15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oil-in-water (o/w) cream applied 2x/day for 4 consecutive days in ACD study
Trial: 31026125
Drug: Salt-related knowledge,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salt-related knowledge, attitudes, and practices (KAP) intervention; specific details on dosage and duration not available.
Trial: 31026125
Drug: Advice to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Advice to lower salt intake; specific details on dosage and duration not available.
Trial: 31026125
Drug: Checking salt/sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Checking salt/sodium labels in food; specific details on dosage and duration not available.
Trial: 31026125
Drug: Adding extra
RxNorm normalized name: Panadol Extra
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adding extra salt to food at the table; specific details on dosage and duration not available.
Trial: 31026125
Drug: Reporting high
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reporting high amounts of salt consumption; specific details on dosage and duration not available.
Trial: 23070341
Drug: Goal-directed lactated
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Goal-directed lactated Ringer's solution
Trial: 23070341
Drug: Goal-directed hydroxyethyl
RxNorm normalized name: Hydroxyethyl Cellulose
DrugBank: Hydroxyethyl cellulose (DB11602)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Goal-directed hydroxyethyl starch solution (6% hydroxyethyl starch solution 130/0.4)
Trial: 23070341
Drug: Restrictive lactated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Restrictive lactated Ringer's solution
Trial: 15812751
Drug: Adriamycin chemotherapy
RxNorm normalized name: Adriamycin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adriamycin chemotherapy (301 ± 52 mg/m²)
Trial: 3153710
Drug: Caffeine (CAF)
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Caffeine (CAF) 10 mg/kg
Trial: 8547856
Drug: Tryptophan (Trp)
RxNorm normalized name: Tryptophan
DrugBank: Tryptophan (DB00150)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tryptophan (Trp) 1.2 g
Trial: 8547856
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Caffeine and Tryptophan (CAF+Trp)
Trial: 1493533
Drug: Occlusive dressing
RxNorm normalized name: DSG Pak with Occlusive Dressing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Occlusive dressing technique using cream (without silicone oil)
Trial: 3991916
Drug: Cimetidine (1.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine (1.6 g daily) for 24 h before and during the starvation period
Trial: 29129441
Drug: Chemotherapy (investigator-choice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (investigator-choice platinum-doublet chemotherapy, 4-6 cycles)
Trial: 15476516
Drug: OROS-O (controlled-release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OROS-O (controlled-release oxybutynin)
Trial: 15476516
Drug: IR-O (immediate-release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IR-O (immediate-release oxybutynin)
Trial: 8375632
Drug: Intravesical administration
RxNorm normalized name: Valrubicin Intravesical Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravesical administration of 1 mg oestriol
Trial: 24762110
Drug: Calcium carbonate
RxNorm normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcium carbonate supplementation (1000 mg daily, 5 d/wk for 1 year)
Trial: 22467284
Drug: Phase-shifting pure
RxNorm normalized name: Dream Pure BB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phase-shifting pure tone treatment
Trial: 22467284
Drug: Pure tone
RxNorm normalized name: Dream Pure BB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pure tone treatment without phase shifting
Trial: 16124432
Drug: Ivermectin 0.2
RxNorm normalized name: ivermectin 0.272 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ivermectin 0.2 mg/kg for 2 days
Trial: 1440822
Drug: Albendazole 400
RxNorm normalized name: albendazole 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albendazole 400 mg twice daily for 21 days
Trial: 11036840
Drug: Intermittent cyclical
RxNorm normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent cyclical etidronate therapy
Trial: 12610803
Drug: Antirheumatic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antirheumatic therapy alone (control)
Trial: 10501887
Drug: Hyoscine-N-butylbromide (HB)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyoscine-N-butylbromide (HB) 20 mg intraarterially
Trial: 8943590
Drug: bupivacaine 0.125%
RxNorm normalized name: BUPIVACAINE 0.125%/NS INJ 250ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bupivacaine 0.125% with fentanyl 10 micrograms.ml‐1
Trial: 8943590
Drug: bupivacaine 0.125%
RxNorm normalized name: BUPIVACAINE 0.125%/NS INJ 250ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bupivacaine 0.125% with diamorphine 125 micrograms.ml‐1
Trial: 8943590
Drug: pethidine 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pethidine 2.5 mg.ml‐1
Trial: 7034583
Drug: Epidural buprenorphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural buprenorphine (0.15 mg)
Trial: 30630778
Drug: Delamanid (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delamanid (100 mg twice daily for 2 months followed by 200 mg once daily for 4 months)
Trial: 19745649
Drug: Atomoxetine (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atomoxetine (80 mg/d)
Trial: 16871058
Drug: Patient-controlled analgesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient-controlled analgesia with morphine (PCA)
Trial: 11125723
Drug: Cognitive Behaviour
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behaviour Therapy Deferred (CBT-DEF)
Trial: 8079104
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg omeprazole daily at 0800 h (group A)
Trial: 8079104
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg omeprazole every other day (group B)
Trial: 178243
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg glucagon intramuscularly
Trial: 20966820
Drug: Botulinum toxin
RxNorm normalized name: Botulinum toxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum toxin injections to confirm trigger sites followed by surgical deactivation
Trial: 18318728
Drug: Sequential delivery
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential delivery of 595-nm PDL and 1,064-nm Nd:YAG lasers
Trial: 14604019
Drug: 0.65 g/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.65 g/kg dose of alcohol
Trial: 8797620
Drug: Milrinone (50-micrograms/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Milrinone (50-micrograms/kg loading dose, followed by 0.25 microgram/kg/min continuous infusion)
Trial: 8797620
Drug: Milrinone (50-micrograms/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Milrinone (50-micrograms/kg loading dose, followed by 0.5 microgram/kg/min continuous infusion)
Trial: 8797620
Drug: Milrinone (50-micrograms/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Milrinone (50-micrograms/kg loading dose, followed by 0.75 microgram/kg/min continuous infusion)
Trial: 1626173
Drug: RU486 (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RU486 (600 mg) followed by Nalador (intravenous sulprostone)
Trial: 28215130
Drug: Intravenous GLP-1
RxNorm normalized name: Arg34Lys26-(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1[7-37]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous GLP-1 (1.2 pmol/kg/min)
Trial: 19122353
Drug: Exercise advice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise advice and prescription, dietary instructions
Trial: 11843382
Drug: Progestogen-only oral
RxNorm normalized name: vaginal ring with progestogen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Progestogen-only oral contraceptives and progesterone vaginal ring
Trial: 9760010
Drug: Lubeluzole 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lubeluzole 2.5 mg, 5 mg, and 10 mg
Trial: 9760010
Drug: Lubeluzole 15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lubeluzole 15 mg, 20 mg, and 25 mg
Trial: 7930388
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone (GH) stimulation with arginine (0.5 g/kg bw) and recombinant GH (4 IU im) in Group 2 (normal IGF-I range)
Trial: 7930388
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone (GH) stimulation with arginine (0.5 g/kg bw) and recombinant GH (4 IU im) in Group 1 (abnormally low IGF-I concentration)
Trial: 23439168
Drug: Stepwise self-titration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stepwise self-titration of oral glucose-lowering medication with self-monitoring and remote nurse monitoring
Trial: 23439168
Drug: Intervention group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention group patients changing their oral glucose-lowering medication
Trial: 23439168
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group patients changing their oral glucose-lowering medication
Trial: 20528837
Drug: 5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg/kg thiamylal
Trial: 3877474
Drug: 1.5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 mg/kg propofol
Trial: 17562958
Drug: Intramyocardial injection
RxNorm normalized name: ALCOHOL 80 mL in 100 mL INTRAEPICARDIAL LIQUID [80% Alcohol Hand Sanitizer]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramyocardial injection of autologous CD34+ stem cells
Trial: 15486408
Drug: Sitaxsentan (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sitaxsentan (100 mg/d)